This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
InterMune, Roche form new danoprevir deal valued at $175mm
30 Nov 2010
Four years after forming a global development and US co-promotion agreement with Roche for its hepatitis C protease inhibitor danoprevir, InterMune Inc. (respiratory and infectious disease therapeutics) has decided to cease its investment in the drug candidate, thereby terminating that 2006 deal. Roche now has sole ownership, holding worldwide development and commercialization rights.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?